Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine

Prostate

Volumn 72, Issue 9, 2012, Pages 1023-1034

  Wayner, Elizabeth A ^a   Quek, Sue Ing ^b,c   Ahmad, Rumana ^b,c   Ho, Melissa E ^b,c   Loprieno, Michelle A ^b   Zhou, Yong ^d   Ellis, William J ^b   True, Lawrence D ^c   Liu, Alvin Y ^b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

AGR2; ELISA; monoclonal antibody; prostate cancer; urine biomarker

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; PROTEIN ANTERIOR GRADIENT 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FILTRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN URINE LEVEL; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; PROSTATIC NEOPLASMS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861094288     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21508     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA,. Prevalence of prostate cancer among men with a prostate-specific antigen level
3. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG,. Are multiple markers the future of prostate cancer diagnostics? Clin Biochem 2004; 37 (7): 519-528.
4. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW,. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19 (5): 1193-1200.
5. Sardana G, Dowell B, Diamandis EP,. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54 (12): 1951-1960.
6. Pascal LE, Vêncio RZN, Page LS, Liebeskind ES, Shadle CP, Troisch P, Marzolf B, True LD, Hood LE, Liu AY,. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer 2009; 9: 452.
7. Fradet Y,. Biomarkers in prostate cancer diagnosis and prognosis: Beyond prostate-specific antigen. Curr Opin Urol 2009; 19 (3): 243-246.
8. Ploussard G, de la Taille A,. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7 (2): 101-109.
9. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY,. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005; 43 (3): 249-259.
10. Zhang Y, Forootan SS, Liu D, Barraclough R, Foster CS, Rudland PS, Ke Y,. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007; 10 (3): 293-300.
11. Maresh EL, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY, Goodglick L,. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer 2010; 10: 680.
12. Bu H, Bormann S, Schäfer G, Horninger W, Massoner P, Neeb A, Lakshmanan VK, Maddalo D, Nestl A, Sültmann H, Cato AC, Klocker H,. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 2011; 71 (6): 575-587.
13. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M, Rosenthal A,. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005; 205 (3): 359-376.
14. Halvorsen OJ, Oyan AM, Bø TH, Olsen S, Rostad K, Haukaas SA, Bakke AM, Marzolf B, Dimitrov K, Stordrange L, Lin B, Jonassen I, Hood L, Akslen LA, Kalland KH,. Gene expression profiles in prostate cancer: Association with patient subgroups and tumor differentiation. Int J Oncol 2005; 26 (2): 329-336.
15. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39 (1): 41-51.
16. Kovalev LI, Shishkin SS, Khasigov PZ, Dzeranov NK, Kazachenko AV, Toropygin IIu, Mamykina SV,. Identification of AGR2 protein, a novel potential cancer marker, using proteomics technologies. Prikl Biokhim Mikrobiol 2006; 42 (4): 480-484.
17. Anderson L, Hunter CL,. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006; 5 (4): 573-588.
18. TM PCA3 test for prostate cancer. Expert Rev Mol Diagn 2011; 11 (2): 137-144.
19. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM,. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3 (94): 94ra72.
20. True LD, Zhang H, Ye M, Huang CY, Nelson PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD, Ellis WJ, Liebeskind ES, Liu AY,. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol 2010; 23 (10): 1346-1356.
21. Liu AY, Zhang H, Sorensen CM, Diamond DL,. Analysis of prostate cancer by proteomics using tissue specimens. J Urol 2005; 173 (1): 73-78.
22. Wayner EA, Hoffstrom BG,. Development of monoclonal antibodies to integrin receptors. Meth Enzymol 2007; 426: 117-153.
23. Liu AY, Roudier MP, True LD,. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 2004; 165 (5): 1543-1556.
24. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ,. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008; 54 (1): 53-60.
25. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson IM, Thornquist M, Winget M, Yasui Y,. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93 (14): 1054-1061.
26. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD,. Pivotal evaluation of the accuracy of a biomarker used for classifciation or prediction: Standards for study design. J Natl Cancer Inst 2008; 100 (20): 1432-1438.
27. Ptolemy AS, Rifai N,. What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scand J Clin Lab Invest Suppl 2010; 242: 6-14.
28. McNeal JE,. Cancer volume and site of origin of adenocarcinoma in the prostate: Relationship to local and distant spread. Hum Pathol 1992; 23 (3): 258-266.
29. Cohen SM, Ellwein LB,. Cell proliferation in carcinogenesis. Science 1990; 249 (4972): 1007-1111.
30. Friberg S, Mattson S,. On the growth rates of human malignant tumors: Implications for medical decision making. J Surg Oncol 1997; 65 (4): 284-297.
31. Gaster RS, Xu L, Han S, Wilson RJ, Hall DA, Osterfeld SJ, Yu H, Wang SX,. Quantification of protein interactions and solution transport using high-density GMR sensor arrays. Nat Nanotechnol 2011; 6 (5): 314-320.
32. Deutsch EW, Lam H, Aebersold R,. PeptideAtlas: A resource for target selection for emerging targeted proteomics workflows. EMBO Rep 2008; 9 (5): 429-434.
33. Hober S, Uhlén M,. Human protein atlas and the use of microarray technologies. Curr Opin Biotechnol 2008; 19 (1): 30-35.
34. Edgell TA, Barraclough DL, Rajic A, Dhulia J, Lewis KJ, Armes JE, Barraclough R, Rudland PS, Rice GE, Autelitano DJ,. Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci 2010; 118 (12): 717-725.
35. Rice GE, Edgell TA, Autelitano DJ,. Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer. J Exp Clin Cancer Res 2010; 29: 62.
36. + prostate tumor-associated stromal cells involves potential organ-specific genes. BMC Cancer 2009; 9: 317.